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Abstract: To investigate the expression of CD44 in colorectal cancer and examine its association with clinicopathological
features, bcl-2, p53 and long-term outcome, paraffin-embedded tumour specimens from 61 patients with Dukes stage B
(AJCC/UICC stage I) and 39 patients with Dukes stage C (AJCC/UICC stage III) colorectal adenocarcinoma were assessed
by immunohistochemistry. The expression of CD44, bcl-2 and p53 were correlated with 5-year follow-up. Low CD44
expression was present in 30%, moderate in 30% and extensive in 40% of cases. It was not related to patient sex and age but
was related to tumour differentiation, stage and tumour site. No association was demonstrated between CD44 and bcl-2.
However, there was significant evidence of an association between CD44 and p53 in 66 cases in which p53 was previously
assessed. There was a trend towards increased survival in patients whose tumours expressed lower levels of CD44 protein.
When entered into multivariate analysis model, which also included bcl-2 and p53, CD44 staining emerged as an indicator of
poor prognosis in colorectal cancer patients.
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Introduction
Colorectal cancer results from a series of genetic events,
which disorder the normal mechanisms controlling cell
growth [15]. Recent studies have identified CD44 glyco-
proteins as potentially important components of tumour
progression and the metastatic cascade [12, 16]. CD44 was
originally described as a homing receptor on lymphocytes,
mediating lymphocyte interactions with high endothelial
venules [18]. Metastasizing tumour cells and recirculating
(activated) lymphocytes share several properties including
motility and invasive behaviour involving reversible ad-
hesive contacts, accumulation and expansion in draining
lymph nodes, adhesion to vascular endothelium and ex-
travasation. This analogy between circulating lympho-
cytes and tumour dissemination prompted the hypothesis
that malignant cells might use molecules like CD44 for
metastasizing. Experimental and clinical studies have
shown a casual role of specific CD44 isoforms in meta-
stasis formation and documented deregulated CD44 ex-
pression in human cancer [29, 35]. On the other hand,
contradictory reports concerning the biological role of
CD44 in tumourigenesis and its clinical value in prog-
nosis have been also reported [17, 19].
The bcl-2 proto-oncogene is an inhibitor of apoptosis
and may therefore permit the accumulation of genetic
alterations that influence cell division and potentially
contribute to tumour development. The bcl-2 gene is
located at chromosome 18q21 and its product is a 24 kD
protein localized to the nuclear envelope endoplasmic
reticulum and outer mitochondrial membranes [24].
P53 is a tumour suppressor gene that plays a key role
in the control of the cell cycle. Cell proliferation is
inhibited by normal or wild type p53 protein, which acts
by arresting the cell cycle at the G1-S phase to allow
DNA repair to take place. Loss of this activity may lead
to neoplastic transformation. Alteration of this sup-
pressor gene is a common event in colorectal cancer and
has been associated with adverse postoperative outcome
and poor survival [13, 31].
The aim of this study was to investigate CD44 im-
munoreactivity in colorectal carcinoma and to determine
its association with clinicopathological features, bcl-2,
p53 and with long-term outcome.
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Materials and methods
Patients. A series of 100 patients underwent surgical resection for
primary colorectal adenocarcinoma at the 3rd Department of
Surgery, Tzanio Hospital of Athens between 1995 and 1999. Cases
of non-inherited polyposis colorectal cancer (NHPCC), familial
adenomatus polyposis (FAP) or ulcerative colitis and patients who
died in the immediate postoperative period were excluded from this
study. None of the patients had received pre- or postoperative
radiotherapy or chemotherapy. Each patient was regularly followed
up at six-month intervals for a minimum of 5 years. Clinical staging
was based on Dukes classification and on clinical evaluation includ-
ing preoperative chest x-ray, abdominal ultrasonography or com-
puted tomography and abdominal exploration during laparotomy.
Tumours were histologically classified as well differentiated, moder-
ately differentiated or poorly differentiated adenocarcinomas using
the WHO criteria [36]. Survival time was calculated from the date of
surgery to the date of death or last follow-up with times censored
from patients dying of causes unrelated to colorectal cancer and those
surviving. Median follow-up was 7 years (from 5 to 9 years).
Tissue specimens and immunohistochemistry. Sections from the
colorectal adenocarcinoma and normal mucosa at the proximal/distal
resection margins were obtained at surgical resection. The slides
were reviewed by two pathologists. For every case, one paraffin
block with both tumour tissue and normal mucosa was selected for
the immunohistochemical detection of CD44, bcl-2 and p53 protein
expression.
Five-micrometer thick sections were mounted on glass slides
coated with APS (aminopropylmethoxysilane), dewaxed in xylene
and rehydrated with graded alcohols. Endogenous peroxidase was
blocked with 3% H2O2 for 15 min. Before application of the primary
antibody, sections were immersed in 10 mM citrate buffer (pH 6.0),
rinsed in TBS and heated in a microwave oven (650-800 W) for three
cycles of 5 min. In order to reduce nonspecific binding of antisera,
sections were washed with TBS before application of the primary
antibodies: anti-CD44 (clone DF 1485, dilution 1:100, Biogenex),
anti-bcl-2 (dilution 1:10, Biogenex) and anti-p53 (DO-7, dilution
1:100 Biogenex) against both wild and mutated forms. Sections were
subsequently treated with the secondary antibody for 30 min and
incubated with ABC (avidin-biotin-peroxidase complex) for 30 min.
Diaminobenzidine (DAB) was used as a chromogen followed by
slight hematoxylin counterstaining. Omission of the primary anti-
body served as negative control.
In order to evaluate CD44 immunostaining, tumour cells showing
cytoplasmic or membraneous staining were regarded as positive. A
cut-off <10% of positive neoplastic cells was used to define low
expression, 10-50% to define moderate expression and >50% to
define extensive expression.
Immunoreactivity for bcl-2 was evaluated according to the per-
centage of tumour cells with positive cytoplasmic staining. A cut-off
<5% of positive tumour cells was used to define negative cases.
Strong positive staining was seen in infiltrating lymphocytes within
the tumour stroma. The infiltrating lymphocytes and the neurones
were used as positive control.
Immunoreactivity for p53 was evaluated semiquantitatively by
two observers and according to the percentage of positive tumour
nuclei, scored as follows: "negative" for tumours showing <10% of
immunostained nuclei, "low" for tumours showing 10-50% of im-
munoreactive nuclei and "high" for tumours with nuclear immunore-
activity in >50% of tumour cells. For positive controls of p53
expression, we used a known laryngeal carcinoma case with diffuse
p53 nuclear immunostaining.
Statistical analysis. All analyses were performed using the Minitab
and SPlus statistical packages. Categorical variables were assessed
by chi-squared analysis or Fisher’s exact test as appropriate. Kaplan-
Meier survival curves were constructed and differences in survival
between groups were compared using the log-rank test. Multivariate
analyses were performed with the Cox proportional hazards model.
Results
Examples of immunostaining are shown in Figures 1-3.
CD44 expression
Low CD44 expression (<10% of neoplastic cells) was
present in 30%, moderate (10-50% of neoplastic cells)
in 30% and extensive (>50% of neoplastic cells) in 40%
of cases. In the normal colorectal mucosa, the cell sur-
face CD44 immunoreactivity was confined to the basal
part of the crypts and was expressed in under 10% of
crypt cells. There were different staining patterns of
CD44 localization: in the normal mucosa, CD44 was
expressed in the superficial part of the cell, while in the
most carcinomas the staining was localized in the baso-
lateral region of the cell. CD44 expression was found in
some lymphocytes and macrophages used as internal
controls. Nerve fibres in the submucosa and muscularis
externa also showed strong staining of myelin sheaths.
The relationship between CD44 expression and a
range of clinicopathological variables is summarised in
Table 1. There was a significant correlation between
CD44 staining and tumour differentiation (P = 0.0295),
as well as tumour stage (P = 0.009) and tumour site (P
= 0.000) mainly reflecting the rectal tumours. No signi-
ficant association was demonstrated between CD44 and
bcl-2 status (Tab. 2). However, there was a significant
evidence of an association between CD44 and p53 status
(P = 0.000), in 66 cases in which p53 had previously
been assessed (Tab. 3).
Survival analysis
The patients were followed-up for an average of 5 years.
Overall, there was a trend towards increased survival in
patients whose tumours expressed lower percentages of
CD44 protein (P = 0.0004, Fig. 4) and who had tumours
expressing bcl-2 protein (P<0.0001, Fig. 5). There was
also a statistically significant correlation (P = 0.0002)
between survival and p-53 expression (Fig. 6). When
entered into a multivariate analysis model (Tab. 4)
which also included bcl-2 and p53, CD44 immunostain-
ing emerged as a prognostic indicator variable: patients
with >50 % of CD44-positive cells were associated with
higher risk of death when compared to patients with
<50% CD44-positive cells. In addition, positive bcl-2
expression was related to lower risk of death.
Discussion
Colorectal cancer is a common disease in Western
World and it is one of the most frequent neoplastic
diseases in the human population, just after the lung and
32 H. Zavrides et al.
prostate cancer in men and breast, lung and cervical
cancer in women. It evolves through a series of morpho-
logically recognizable stages known as the adenoma-
carcinoma sequence. Molecular genetics has increased
our understanding of the development of colorectal
cancer [22, 28]. Tumour progression is characterized by
a stepwise accumulation of specific molecular alter-
ations, ultimately resulting in invasive and metastatic
Fig. 1. Immunohistochemical staining of CD44 in colon adenocarcinoma. Fig. 2. Adenocarcinoma of the colon with positive immunostaining
for bcl-2. Fig. 3. Expression of p53 in colon adenocarcinoma. Fig. 4. Survival of 100 patients with colorectal cancer stratified by CD44
immunohistochemical staining: <10% (n = 30), 10-50% (n = 30), >50% (n = 40). Fig. 5. Survival of 100 patients with colorectal cancer
stratified by bcl-2 immunohistochemical staining: bcl-2-negative (<5%) (n = 73), bcl-2-positive (>5%) (n = 27). Fig. 6. Survival of 100
patients with colorectal cancer stratified by p53 expression: p53-negative (<10%) (n = 34), low p53 (10-50%) (n = 27), high p53 (>50%) (n
= 39). 
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cancer. Most of the molecules cause either genetic insta-
bility or act on the regulation of the cell cycle, resulting
in a disturbed homeostasis between cell proliferation and
apoptosis. However, the growth of the primary tumour
is not the main cause of the cancer-related death - it is
the formation of the metastases in distant organs. A
number of studies indicate an important role for CD44
in this complicated process [29, 35, 37].
CD44 is a widely distributed transmembrane glyco-
protein that has been proved to function as a major
cell-surface receptor for glycosaminoglycan hyaluro-
nate and to play an important role in cell-cell and cell-
extracellular matrix interactions such as lymphopoiesis,
myelopoiesis, lymphocyte homing, macrophage activa-
tion and tumour progression and metastasis. This trans-
membrane glycoprotein molecule is expressed as a
standard form (CD44H) and as numerous splice variants
(CD44V) [26]. However, the role of CD44 in epithelial
metastases is not clear. Some studies suggest that a high
level of expression of the variant form of CD44 may be
important in tumour invasion, and CD44 has been linked
to the development and spread of malignancies [1, 3, 7,
27]. It has been also shown that in lymphomas, as well
as in gastric and cervical carcinomas, high CD44 ex-
pression is correlated with more advanced tumour stage
and possibly with poor prognosis [6, 7]. On the other
hand, there are studies in which down-regulation or
absence of CD44 indicate aggressiveness [14, 25], or the
expression of the CD44 variant epitopes does not corre-
late with either tumour progression or metastasis to the
liver from colorectal carcinoma [11]. It is possible that
discrepant results between studies reflect the use of
diverse antibodies that may have subtle differences in
specificity. The problem is complicated by the existence
of numerous CD44 isoforms, which may have remark-
able homology in their antigenic repertoire, increasing
the possibility of cross-reactivity between the anti-
bodies [9] . Another source of such discrepancies is
probably comparison of results obtained with differ-
ent techniques [8].
Tissue growth depends on both cell proliferation and
the rate of cell death [21]. Thus, it is conceivable that
neoplastic growth may be caused or promoted by factors
inhibiting cell death. Bcl-2 is a proto-oncogene involved
in the regulation of cell death by inhibiting apoptosis in
many cell systems in physiologic and neoplastic condi-
tions [30]. Investigations of bcl-2 in colorectal carcino-
ma have yielded conflicting survival results. Kouraklis
et al. [23] and Tollenaar et al. [33] did not find any
prognostic significance of bcl-2 expression. In contrast,
Table 1. Clinical and pathological features of 100 patients with
colorectal cancer stratified by CD44 status
Variable
CD44 immunohistochemistry
<10% 10-50% >50% P-value
Sex
Male
Female
14
16
14
16
25
15 0.299*
Age (years)
Median 69.50 68.00 70.50 0.656a
Tumour stage
Stage B
Stage C
25
 5
14
16
22
18 0.009*
Tumour site
Rectum
Left colon
Right colon
28
 1
 1
22
 6
 2
 7
16
17
0.000b
Tumour grade
Well/moderately
differentiated
Poorly
differentiated
30
 0
28
 2
33
 7
0.0295b
*Chi-squared test, aKruskal-Wallis test, bFisher’s exact test
Table 2. CD44 expression and bcl-2 status in 100 cases of colorectal
cancer
CD44 immunohistochemistry
bcl-2 
(n = 100) <10% 10-50% >50% P-value
Negative (%)
(n = 73) 23 22 28
0.823*
Positive (5%)
(n = 27)  7  8 12
*Chi-squared test
Table 3. CD44 expression and p53 status in 66 cases of colorectal
cancer
CD44 immunohistochemistry
P53 (n = 66) <10% 10-50% >50% P-value
Low staining
(10-50%)
(n = 27)
10 12  5
0.000b
High staining
(50%)
(n = 39)
 1  3 35
bFisher’s exact test
Table 4. Cox regression model including CD44, bcl-2 and p53
Variable Coefficient Standard error P-value
CD44 0.855 0.289 0.00305
bcl-2 -1.164 0.355 0.00109
p53 0.326 0.316 0.30218
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other authors reported that bcl-2 expression was associ-
ated with a favourable clinical outcome [4, 32].
Mutation of p53 is one of the most frequently en-
countered genetic alterations in solid tumours. Such
mutations play a central role in colorectal tumour pro-
gression and are present in 50% of sporadic colorectal
carcinomas [20]. Numerous investigations have dealt
with the prognostic significance of p53 aberrations in
colorectal adenocarcinoma, providing contradictory re-
sults [34].
The gene mutations produce metabolically more
stable proteins that may be used as prognostic indicators
in patients with colorectal cancer [5]. In our study with
a 5-year follow-up, expression of CD44 was not related
to patient sex and age but was related to tumour differen-
tiation, stage and site. No significant association was
demonstrated between CD44 and bcl-2 status. However,
there was a significant evidence of an association be-
tween CD44 and p53 status in 66 cases in which p53 had
previously been assessed. When entered into a multi-
variate analysis model, which also included bcl-2 and
p53, CD44 staining emerged as a prognostic indicator
variable.
Both distant metastases and local recurrence after
curative operation are the major causes of death in
cancer patients. Several studies have been focused on
markers to indicate metastatic potential of tumour cells
and to predict prognosis. Carcinoma progression is a
complex multistep process involving multiple modifica-
tion of cell surface components, intracellular alterations
and genetic changes [2, 10]. CD44 is one of various
adhesion molecules. Our study suggests that its express-
ion in colorectal cancer is associated with poor prog-
nosis. Hence, immunohistochemical evaluation of
CD44 in colorectal cancer may be of clinical value.
Further studies should determine which portion and
which function of the CD44 molecule are associated
with the metastatic potential of tumour cells.
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